Loading clinical trials...

HAPH Registry: Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders. | Clinical Trials | Clareo Health

NOT_YET_RECRUITING

HAPH Registry: Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.

NCT06489730•University of Zurich

View on ClinicalTrials.gov

Summary

The purpose of the current study is to evaluate the clinical and physiologic course of Kyrgyz highlanders with high altitude pulmonary hypertension (HAPH) by performing a longitudinal cohort study. To this end, the investigators will invite the same highlanders who participate din the study in 2017 to undergo follow-up examinations in 2024, in order to allow comparisons of current results with baseline data from 2017.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Permanently living \>2500 m
•Written informed consent

Exclusion Criteria

•Highlanders who cannot follow the study investigations,
•Patients with moderate to severe concomitant lung disease (FEV1\<70% or forced vital capacity \<70%), severe parenchymal lung disease, heavy smoking \>20 cigarettes/day or \>20 pack-years.
•Coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months
•Regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)

Key Dates

Start Date

July 1, 2024

Primary Completion Date

December 31, 2024

Completion Date

December 31, 2024

Last Updated

July 8, 2024

Enrollment

120

ESTIMATED participants

Conditions

High Altitude Pulmonary HypertensionSleep Apnea

Contacts

Silvia Ulrich, Prof. Dr.

CONTACT

+41442552220 silvia.ulrich@usz.ch

Michael Furian, Prof. Dr.

CONTACT

+41442552220 michael.furian@usz.ch

OSA Risk Level in Dental Patients and Correlation With Complications After General Anesthesia

NCT06430957

Obstructive Sleep Apnea Risk ManagementPostoperative Complications+2 more

View study

RECRUITINGNA

Digital-supported Orofacial Myofunctional Therapy in OSA

NCT07292922

Obstructive Sleep Apnea (OSA)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 8, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

HAPH Registry: Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.

Inclusion Criteria

Exclusion Criteria

OSA Risk Level in Dental Patients and Correlation With Complications After General Anesthesia

Digital-supported Orofacial Myofunctional Therapy in OSA

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Maxillomandibular Advancement Surgery for Treatment of Obstructive Sleep Apnoea Syndrome

Spanish Registry of Patients With Sleep Apnea and Daytime Sleepiness

A Cross-sectional Study Examining Adipose Tissue in Obstructive Sleep Apnea